PyInvesting

Market research

2877.HK China Shineway Pharmaceutical Group Limited

HK HKD Healthcare

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
6B
P/E ratio
5.48
Analyst target
9.2544
Dividend yield
5.7%
Beta
0.72

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 4 months ago

China Shineway Pharmaceutical Group Limited is currently in a long term uptrend where the price is trading 27.5% above its 200 day moving average.

From a valuation standpoint, the stock is 98.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.

China Shineway Pharmaceutical Group Limited's total revenue rose by 9.6% to $1B since the same quarter in the previous year.

Its net income has dropped by 80.8% to $41M since the same quarter in the previous year.

Finally, its free cash flow grew by 931.6% to $171M since the same quarter in the previous year.

Based on the above factors, China Shineway Pharmaceutical Group Limited gets an overall score of 4/5.